IL128771A0 - An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof - Google Patents

An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof

Info

Publication number
IL128771A0
IL128771A0 IL12877197A IL12877197A IL128771A0 IL 128771 A0 IL128771 A0 IL 128771A0 IL 12877197 A IL12877197 A IL 12877197A IL 12877197 A IL12877197 A IL 12877197A IL 128771 A0 IL128771 A0 IL 128771A0
Authority
IL
Israel
Prior art keywords
enhancing
activity
agent
glutathione reductase
reductase containing
Prior art date
Application number
IL12877197A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL128771A0 publication Critical patent/IL128771A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12877197A 1996-09-12 1997-09-11 An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof IL128771A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24191096 1996-09-12
PCT/JP1997/003199 WO1998010760A1 (fr) 1996-09-12 1997-09-11 Potentialisateur d'activite de glutathione-reductase contenant de la troglitazone

Publications (1)

Publication Number Publication Date
IL128771A0 true IL128771A0 (en) 2000-01-31

Family

ID=17081372

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12877197A IL128771A0 (en) 1996-09-12 1997-09-11 An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof

Country Status (12)

Country Link
EP (1) EP0958818A1 (xx)
KR (1) KR20000036035A (xx)
CN (1) CN1235543A (xx)
AU (1) AU723354B2 (xx)
CA (1) CA2265656A1 (xx)
CZ (1) CZ74199A3 (xx)
HU (1) HUP0002941A3 (xx)
ID (1) ID21778A (xx)
IL (1) IL128771A0 (xx)
NO (1) NO991205L (xx)
NZ (1) NZ334577A (xx)
WO (1) WO1998010760A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
AP2001002036A0 (en) * 1998-07-21 2001-03-31 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
WO2000007582A2 (en) * 1998-08-06 2000-02-17 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
US6379664B1 (en) 1998-09-29 2002-04-30 Board Of Regents University Of Nebraska-Lincoln Composition and method for the prevention and treatment of oxidative damage in ocular tissues
AU3073600A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
JPS6136284A (ja) * 1984-07-27 1986-02-20 Sankyo Co Ltd チアゾリジン誘導体およびその製造方法
JPH0653738B2 (ja) * 1985-02-26 1994-07-20 三共株式会社 チアゾリジン誘導体
JPS62234085A (ja) * 1985-12-18 1987-10-14 Sankyo Co Ltd チアゾリジン誘導体を有効成分とする糖尿病性合併症治療剤
WO1988000182A1 (en) * 1986-07-07 1988-01-14 Teijin Limited gamma-L-GLUTAMYL-L-CYSTEINE ETHYL ESTER AND DRUG CONTAINING IT AS EFFECTIVE INGREDIENT
JP2553090B2 (ja) * 1987-07-21 1996-11-13 帝人株式会社 組織グルタチオンレベル向上剤
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
JPH0651189A (ja) * 1992-08-04 1994-02-25 Kyocera Corp オートフォーカス一眼レフカメラの近接撮影機構
JP2945220B2 (ja) * 1992-10-23 1999-09-06 旭カーボン株式会社 ハード系高ストラクチャーカーボンブラック

Also Published As

Publication number Publication date
NO991205L (no) 1999-05-11
HUP0002941A3 (en) 2001-11-28
NO991205D0 (no) 1999-03-11
ID21778A (id) 1999-07-22
AU723354B2 (en) 2000-08-24
CN1235543A (zh) 1999-11-17
NZ334577A (en) 2001-03-30
KR20000036035A (ko) 2000-06-26
AU4219597A (en) 1998-04-02
WO1998010760A1 (fr) 1998-03-19
HUP0002941A2 (hu) 2001-08-28
CA2265656A1 (en) 1998-03-19
EP0958818A1 (en) 1999-11-24
CZ74199A3 (cs) 1999-07-14

Similar Documents

Publication Publication Date Title
AU1387400A (en) Verification of software agents and agent activities
AU8140898A (en) Inhibitors of beta-lactamases and uses therefor
EP1018987A4 (en) NEO-CARTILAGE AND ITS METHODS OF USE
HUP0004592A3 (en) Compounds and methods for the inhibition of the expression of vcam-1
EP1071706A4 (en) FAST DEGRADABLE GFP FUSION PROTEINS AND METHOD OF USE THEREOF
IL157745A0 (en) Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
IL132146A0 (en) Composition for the detection of electrophilic gases and methods of use thereof
IL183948A0 (en) Conjugates of peg-urate oxidase and use thereof
EP1024130A4 (en) BIPHENYL-5-ALKANIC ACID DERIVATIVES AND THEIR USE
EP1033910A4 (en) DIPEPTIDE APOPTOSE INHIBITORS AND THEIR USE
HU9802721D0 (en) Method and composition for the treatment and prevention of hyperuricemia
PL341335A1 (en) Combination of ace and mmp inhibitors
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU9565598A (en) Use of the tumour suppressor gene p33ing1 for modulation of p53 activity and in tumour diagnosis
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
PL341709A1 (en) Structural combination of rubber and metal
IL128101A (en) Detection of mammalian heparanase activity and kit for such detection
AU9197598A (en) Inducing neurotransmitter and neuropeptide activity
IL128771A0 (en) An agent for enhancing the activity of glutathione reductase containing troglitazone and use thereof
EP1053988A4 (en) trimethylcyclohexane derivatives and melanin-forming inhibitors, and perfume-containing agents containing them
HUP9800146A3 (en) Thalidomide-derivatives and use of them
HK1039140A1 (zh) 塗布劑及其用途
AU8622898A (en) Closure for containers and use of the closure
HU9802512D0 (en) Methods and compositions for enhancing herbicidal activity
IL128399A0 (en) Use of hCG and derivatives thereof in the inhibition of MMP enzymatic activity